Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have taken the weight-loss world by storm. Even beyond the healthcare world, Ozempic, Wegovy and Mounjaro have become household names as they have skyrocketed in popularity.
Their success has led developers Eli Lilly and Novo Nordisk to realise the potential of oral GLP-1RAs, with both companies having come to the end of Phase III trials of their respective drugs, orforglipron and oral semaglutide, in obesity
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Both are now seeking approval, with Lilly set to file for approval of its oral therapy in obesity by the end of 2025, and Novo Nordisk having already submitted its request to the US Food and Drug Administration (FDA).
In this episode of GlobalData’s Healthcare podcast, Abigail Beaney, editor of Clinical Trials Arena speaks with Robert Barrie, editor of Pharmaceutical Technology, about recent studies from Eli Lilly and Novo Nordisk and how analysts are feeling about the wave of oral GLP-1RAs. Abigail will also be speaking with Dr Katherine Saunders, an obesity physician and co-founder of FlyteHealth, about how the use of these drugs will look in the clinic.
